PET imaging of amyloid-beta (Aβ) deposits in brain has become an important aid in Alzheimer's disease diagnosis, and an inclusion criterion for patient enrolment into clinical trials of new anti-Aβ treatments. Available PET radioligands visualizing Aβ bind to insoluble fibrils, i.e. Aβ plaques. Levels of prefibrillar Aβ forms, e.g. soluble oligomers and protofibrils, correlate better than plaques with disease severity and these soluble species are the neurotoxic form of Aβ leading to neurodegeneration. The goal was to create an antibody-based radioligand, recognizing not only fibrillary Aβ, but also smaller and still soluble aggregates. We designed and expressed a small recombinant bispecific antibody construct, di-scFv 3D6-8D3, targeting the Aβ N-terminus and the transferrin receptor (TfR). Natively expressed at the blood-brain barrier (BBB), TfR could thus be used as a brain-blood shuttle. Di-scFv 3D6-8D3 bound to Aβ1-40 with high affinity and to TfR with moderate affinity. Di-scFv [
Introduction
The introduction of [ 11 C]Pittsburgh compound B ([ 11 C]PIB) 15 years ago was a breakthrough in molecular imaging greatly assisting in the diagnostic process of Alzheimer's disease (AD), as it enabled visualization of amyloid beta (Aβ) plaque load in living human brain (Klunk et al., 2004) . While [ 11 C]PIB detects AD pathology early during disease progression, [ 11 C]PIB PET signal remains static as AD patients deteriorate clinically (Engler et al., 2006; Rodriguez-Vieitez et al., 2016) . Furthermore, carriers of familial Arctic AβPP mutations and patients with diffuse plaque pathology have low cortical PIB retention levels due to lack of fibrillar Aβ, leading to negative PIB PET scans, evidently showing a limitation of PIB PET (Sch€ oll et al., 2012) . It also appears that levels of soluble Aβ correlate better than plaques with disease severity and that soluble Aβ aggregates, e.g. oligomers and protofibrils, are the neurotoxic form of Aβ that leads to neurodegeneration (Esparza et al., 2013; McLean et al., 1999; Walsh et al., 2002) . In this perspective, a radioligand recognizing not only fibrillar Aβ, but also smaller and soluble aggregates, protofibrils, would be of significant clinical value.
Radiolabeled antibodies have been adapted as PET radioligands in oncology (Van Dongen et al., 2012) . The high specificity of an antibody for its antigen makes it an attractive option as a radioligand, as a high specific-to-nonspecific signal ratio is desirable. However, antibodies are large molecules (>150 kDa) and thus are hindered by the blood-brain barrier (BBB) from entering the brain due to tight junctions between endothelial cells, which strongly limit transcellular passage. Indeed, less than 0.1% of injected antibody dose enters the brain (Bard et al., 2000; Poduslo et al., 1994) . Hence, a facilitated mechanism of passage across the BBB is required for antibody delivery to the intact brain.
One such method is to utilize the transferrin receptor (TfR), an ironshuttling receptor, expressed on the endothelial surface of the BBB. TfR has been demonstrated to function as a mechanism for ferrying therapeutics, including antibodies, across the BBB (Niewoehner et al., 2014; Pardridge et al., 1991) . Previously, we have created a chemically conjugated bispecific fusion protein (8D3-F(ab') 2 -h158) targeting protofibrillar Aβ and TfR, which, after radiolabeling, was successfully used as an immuno-PET radioligand in mice over-expressing human Aβ (Sehlin et al., 2016) . However, chemical conjugation leads to a heterogeneous mixture which is an impediment to further development of 8D3-F(ab') 2 -h158 into a clinical PET ligand. Further, 8D3-F(ab') 2 -h158 binds TfR bivalently, while recent research suggests monovalent and/or low affinity TfR binding increases BBB passage (Niewoehner et al., 2014; Yu et al., 2011) . We therefore designed and expressed a bispecific fusion protein, RmAb158-scFv8D3, as a homogeneous preparation . Moreover, RmAb158-scFv8D3 has a scFv 8D3 attached with a short, inflexible linker sequence to the C-terminal of both light chains, preventing bivalent TfR binding; RmAb158-scFv8D3 displayed a five-fold increased brain uptake (approximately 2-3% of injected dose, similar to small molecules) compared with its chemically conjugated predecessor 8D3-F(ab') 2 -h158 . However, RmAb158-scFv8D3, as well as 8D3-F(ab') 2 -h158, are large proteins (203 kDa and 270 kDa, respectively) with intact Fc domains and hence display long biological half-life in blood which make them less suited as radioligands for clinical use. To obtain faster clearance of radiolabeled antibody-based ligand from blood, we designed a recombinant Tribody™ radioligand composed of two scFv fragments of mAb158 fused to Fab 8D3 (no Fc domain) and used it for brain PET (Syv€ anen et al., 2017) . The Tribody™ has a size of 100 kDa and it displayed a half-life in blood of approximately 9 h, i.e. substantially faster clearance compared to both 8D3-F(ab') 2 -h158 (12 h) and .
3D6 is the murine parent antibody of bapineuzumab, a humanized monoclonal antibody that has undergone clinical trials as an anti-Aβ treatment for AD. However, these trials have been discontinued since they did not reach their primary endpoint (i.e. cognitive improvement), although there was reduction in Aβ levels (Ivanoiu et al., 2016; Rinne et al., 2010) . It has been shown previously that a truncated form of 3D6 (i.e. Fab 3D6) lacking the Fc domain retains its binding capability to its target, namely amino acids 1-5 of the Aβ N-terminus (Feinberg et al., 2014; Miles et al., 2013) . Based on this, we here designed a new recombinant bispecific fusion protein (di-scFv 3D6-8D3) composed of two single-chain variable fragments (scFv) linked together expressed as one construct. The di-scFv 3D6-8D3 fusion protein is composed of the variable regions of the heavy and light chain of 3D6 and of 8D3 (which binds to TfR).
Expressing a scFv variant of 8D3 allows for monovalent TfR binding which is beneficial for efficient BBB passage. Furthermore, while bispecific fusion proteins based on full length antibodies cross the BBB in sufficient concentrations to enable PET (Sehlin et al., 2016) , the di-scFv 3D6-8D3 fusion protein has a predicted size of approximately 58 kDa, which is about one third of full length antibodies and significantly smaller than the antibody-based PET ligands we have described previously Sehlin et al., 2016; Syv€ anen et al., 2017) . Due to its small size, di-scFv 3D6-8D3 is likely to have a shorter biological half-life in blood (Adams et al., 1993; Goel et al., 2000; Stork et al., 2009 ).
The goal of this project was to create a novel PET radioligand targeting Aβ with an approach based on recombinant antibody design. If successful, this novel PET radioligand could be used for visualization of all forms of soluble Aβ. This can be compared to conventional PET radioligands used today that visualize solid Aβ plaques only, i.e. [ 11 C]PIB and analogues. By recombinantly expressing a 58 kDa di-scFv fusion protein composed of Aβ N-terminus recognizing 3D6 and TfR-binding 8D3, we improved BBB passage leading to elevated concentrations in brain, while half-life in blood was shortened so same day PET imaging could be performed.
Material and methods
For details regarding cloning, expression, and in vitro validation of discFv 3D6-8D3, see Supplementary info.
Animal models
Two mouse models were used: tg-Swe mice harbouring the Swedish AβPP (KM670/671NL) mutation, and tg-ArcSwe expressing Swedish (KM670/671NL) and Arctic (E693G) mutations. These are maintained on a C57BL/6 background, and are models of Aβ pathology related to AD (Lord et al., 2006) . The tg-ArcSwe model has elevated soluble Aβ protofibril levels and enhanced intraneuronal Aβ aggregation detectable at 4 months, and visible plaque pathology starting from 6 months (Lord et al., 2006) . The tg-Swe model has onset of plaque pathology starting at 10-12 months and increasing with age. Males and females were used for the experiments, and wildtype (wt) littermates included as controls. Animals were housed in an animal facility at Uppsala University, with ad libitum access to rodent chow and water, in rooms with constant maintained temperature and humidity. All procedures described here were approved by the Uppsala County Animal Ethics board (#C17/14), following rules and regulations of the Swedish Animal Welfare Agency and were in compliance with the European Communities Council Directive of 22 September 2010 (2010/63/EU). All efforts were made to minimize animal suffering, and to reduce the number of animals.
Human brain
AD postmortem brain tissue was obtained from Netherlands Brain Bank (NBB), Amsterdam, the Netherlands. Autopsies were performed on donors from whom written informed consent had been obtained either from the donor or direct next-of-kin. Clinical diagnosis of demented patients was performed according to NINCDS-ADRDA criteria and dementia severity was estimated according to the Global Deterioration Scale (McKhann et al., 1984; Reisberg et al., 1982) .
Radiochemistry
Di-scFv 3D6-8D3 was iodine-124 labeled using a direct radioiodination method with Chloramine-T (Sigma Aldrich, Stockholm, Sweden), based on electrophilic attack of the phenolic ring of tyrosine residues by in situ oxidized iodine (Greenwood et al., 1963) . In brief, 100 μl of iodine-124 (Perkin-Elmer Inc.) was pre-incubated with 20 μl 50 μM NaI for 15 min prior to addition of 240 pmoles of di-scFv 3D6-8D3, PBS to a total volume of 420 μl, and 40 μg Chloramine-T. Reaction was allowed to proceed for 120 s, and quenched by addition of 80 μl of sodium metabisulfite (1 mg/ml). Di-scFv [ 124 I]3D6-8D3 was purified of free iodine and low-molecular weight components with a disposable NAP-5 size exclusion column with 5 kDa cutoff (GE Healthcare, Uppsala, Sweden) as according to manufacturer's instructions, then eluted in 1 ml PBS. Yield was calculated based on added radioactivity and radioactivity in purified radioligand solution. Radiolabeling was performed no more than 2 h prior to each study.
Di-scFv [ 125 I]3D6-8D3 was radiolabeled similarly.
[ 11 C]PIB was synthesized as described previously (Klunk et al., 2004) .
Autoradiography
Fresh frozen human and mouse brain tissue were sectioned on a cryostat (20 μm) and mounted on SuperFrost Plus slides (Menzel GmbH, Braunschweigh, Germany). Sections were incubated with PBS þ1% BSA, then immersed overnight in PBS containing 0.03 μg/ml di-scFv [ 125 I] 3D6-8D3 (50 MBq/nmol), or with 100-or 500-fold molar excess of unlabeled di-scFv 3D6-8D3. Sections were washed 3 Â 15 min in cold PBS, 30 s in dH 2 O, and dried at 37 C for 10 min. Sections were exposed to phosphor imaging plates (MS, MultiSensitive, PerkinElmer, Downers Grove, IL, USA) overnight. Plates were scanned in a Cyclone Plus phosphor imager (PerkinElmer) at 600 dpi.
PET
Before scanning, animals were given water with 0.2% NaI to reduce thyroidal 124 I uptake. Mice (8 m tg-ArcSwe: n ¼ 3, 12 m tg-ArcSwe: n ¼ 3, 18 m tg-ArcSwe: n ¼ 10, 18 m tg-Swe: n ¼ 8, and wt: n ¼ 7) were intravenously injected with 6.0 AE 2.2 MBq (147 AE 69 MBq/nmol) di-scFv [ 124 I]3D6-8D3. Animals were scanned twice, at 14 h (18 m tg-ArcSwe: n ¼ 4, 18 m tg-Swe: n ¼ 3, wt: n ¼ 2), 24 h (8 m tg-ArcSwe: n ¼ 3, 12 m tg-ArcSwe: n ¼ 3, 18 m tg-ArcSwe: n ¼ 6, 18 m tg-Swe: n ¼ 4, wt: n ¼ 3), and/or at 72 h (8 m tg-ArcSwe: n ¼ 3, 12 m tg-ArcSwe: n ¼ 3, 18 m tgArcSwe: n ¼ 4, 18 m tg-Swe: n ¼ 5, wt: n ¼ 4) post-injection. Animals were anesthetized with 2.5% isoflurane, then positioned on the preheated scanner bed of the small animal microPET/CT (Triumph Trimodality System, TriFoil Imaging, Inc., Northridge, CA, USA). Anesthesia was maintained for entire duration with isoflurane (1.5-2.0%). PET data was acquired in list mode, followed by CT (duration: 3 min, Field of View (FOV): 80 mm)).
A week prior to di-scFv [ 124 I]3D6-8D3 PET, a subset of 18 month old mice, tg-ArcSwe (n ¼ 3), tg-Swe (n ¼ 2), and wt (n ¼ 3), were investigated with [
11 C]PIB immediately after i.v. administration (13.7 AE 3.54
MBq, 33 AE 40 MBq/nmol). Summation of 40-60 min was used for further analysis. PET and CT analysis was performed in Amide 1.0.4. In order to obtain quantified ROI-based data, CT scans were manually aligned to T 2 weighted MRI-based mouse atlas containing outlined ROIs for hippocampus, cortex, cerebellum, and whole brain. By then manually aligning PET scans to CT, the MRI atlas was thus indirectly aligned with PET scans. Radioactivity concentrations over time was obtained expressed as standardized uptake values (SUV, i.e. measured radioactivity per gram tissue/injected radioactivity per gram body weight). In order to quantitatively assess specific binding, the concentration ratio (SUVR) between a brain region known to have high specific retention (e.g. hippocampus) and a region assumed to be void of specific binding (i.e. cerebellum) was calculated. As such, any increase in SUVR above 1 was assumed to be due to elevated concentration of di-scFv [ 124 I] 3D6-8D3 specifically bound to Aβ.
Ex vivo analyses
Blood samples were taken periodically from the tail vein to investigate pharmacokinetics. Following the final PET scan, organs were extracted after intracardial perfusion. For further details, see supplementary info.
Ex vivo autoradiography
Following extraction and flash-freezing, the right hemisphere of selected individuals (n ¼ 1 per group) was cryosectioned (CM1850, Leica Microsystems) and two 20 μm sections per animal and a 124 I dilution standard were exposed to positron sensitive phosphor for 7 days. Plates were scanned in a Cyclone Plus phosphor imager at 600 dpi.
Biochemical and histopathological analyses
Analysis of soluble and total Aβ in brain was performed as described previously . Left cerebrum (left hemisphere minus cerebellum) and left cerebellum were separately homogenized (2 Â 10 s at 4500 rpm) using a Precellys ® Evolution (Bertin Corp.) at 1:5 weight:volume ratio in TBS with complete protease inhibitors (Roche). To measure soluble Aβ, subsequent TBS extract was mixed 1:1 with TBS (total 10x dilution), centrifuged at 16000 g for 1 h at 4 C. For total Aβ, TBS extract was mixed with 96% formic acid to end concentration of 70% formic acid, followed by 10 s vortex and centrifugation as above. Soluble Aβ aggregates were measured by coating 96-well plates overnight with 12.5 ng/well of 82E1, recognizing amino acids 1-5 on N-terminus, (IBL International/Tecan Trading AB), followed by 2 h blocking with 1% BSA. Thereafter, diluted brain extract was incubated overnight at 4 C, followed by 2 h incubation with biotinylated 82E1. For detection, plate was incubated with Streptavidin-HRP for 1 h, followed by development with K-Blue ® Substrate (TMB, 308177, Neogen Life Sciences), halted after 15 min with 1 M H 2 SO 4 .
Statistical analysis
Data were analysed in Graphpad Prism 6.0 with one-way ANOVA with post hoc Bonferroni's to correct for multiple comparisons. Variance was assumed equal. Results are reported as mean AE SD. Pearson's correlation was used to analyse correlation of PET-derived radioligand uptake in brain and ex vivo radioligand concentrations in brain, and radioligand uptake in brain (PET and ex vivo) and Aβ concentration in brain. Significance indicated as per Graphpad Prism 6.0, i.e. *: p < 0.05, **: p < 0.01, ***: p < 0.001, and ****: p < 0.0001. To determine binding affinity to TfR, and to Aβ monomers and protofibrils, one site nonlinear regression fit was performed. K d reported as mean and 95% CI.
Results
In order to verify di-scFv 3D6-8D3 binding to Aβ in mouse and in human tissue, we radiolabeled di-scFv 3D6-8D3 with iodine-125 and performed autoradiography (Fig. 1) . To verify that the binding was Aβ specific, sections were co-incubated with a 100- (Fig. 1a) or 500-fold (Fig. 1b) excess of unlabeled di-scFv 3D6-8D3. There was strong specific binding of di-scFv [ 125 I]3D6-8D3 to anatomical regions known to exhibit Aβ pathology (Philipson et al., 2009 ) in tg-ArcSwe (Fig. 1a) , but no specific binding could be detected in wt mice. Similarly, in human brain [
125 I]3D6-8D3-signal was located in cortical grey matter where Aβ deposits were found. When blocked, the level of specific binding appeared much lower in both human and mouse (Fig. 1b and c) .
Initially with PET at 14 h after administration of di-scFv [ 124 I]3D6-8D3, no visual distinction could be made between age-matched tgArcSwe, tg-Swe, and wt mice (Fig. 2) . After 24 h, wt brain was largely void of di-scFv [ 124 I]3D6-8D3-based PET signal, while signal was present in tg-ArcSwe, and tg-Swe. Signal intensity increased with age, i.e. with pathology progression, in tg-ArcSwe mice. At 72 h, a similar pattern was present, furthermore peripheral tissue surrounding the brain region was devoid of radioactivity. In order to validate the PET scans, ex vivo autoradiography was performed following 72 h PET scans of selected mice (Fig. 2b) . In line with in vivo PET, there was increasing signal with age in tg-ArcSwe, with highest intensity present in 18 m tg-ArcSwe and tg-Swe. The 18 m wt mouse brain was not visible on the autoradiography plate.
Radioactivity concentrations in blood (SUV blood ) rapidly decreased with time (half-life in blood: 3.0 h, 95% CI: 2.3-4.4 h), while brain concentrations remained fairly stable in mice with Aβ pathology, particularly in tg-ArcSwe (Fig. 3a and b) . Brain concentrations were quantified both based on PET-derived signal (Fig. 3a) and on ex vivo postperfusion measured radioactivity (Fig. 3b ) in order to compare di-scFv [ 124 I]3D6-8D3 retention between different groups. At 14 h post administration, there was no significant difference between groups, while at 24 h tg-ArcSwe 18 m showed higher intra brain radioactivity values than other groups. Due to large variation within this group, trend was not statistically significant. At 72 h, 18 m tg-ArcSwe showed significantly higher PET-derived SUV brain than wt mice (p < 0.05). Based on ex vivo SUV brain , there was a significant increase in brain retention of di-scFv [ 124 I]3D6-8D3 in 12 m tg-ArcSwe, 18 m tg-ArcSwe, and 18 m tg-Swe compared with wt mice (p < 0.05, p < 0.0001, p < 0.05, respectively). PET-derived SUV brain resembled ex vivo SUV brain , and there was a strong correlation present (R 2 ¼ 0.848) (Fig. 3c ).
An ROI-based concentration ratio using cerebellum as reference region was generated to investigate specific binding in whole brain and regions known to contain large amounts of Aβ. SUVR was around 1 for wt mice. Since unbound di-scFv [ ]3D6-8D3, there was no significant difference in SUVR based on whole brain ROI between different groups, although all tg-ArcSwe and tg-Swe displayed somewhat higher SUVR in whole brain than wt mice. However, at 24 h, mice with Aβ pathology tended to show an elevated SUVR in whole brain compared with wt mice: 12 m tg-ArcSwe had significantly higher SUVR in whole brain (p < 0.05) and in cortex (p < 0.05), and 18 m tg-Swe had significantly higher cortex ratio (p < 0.01). At 72 h, tg-ArcSwe of all three age groups and tg-Swe mice showed significantly elevated specific binding as per SUVR in whole brain compared with wt mice (Fig. 4a) . Even more evident to what was observed in the whole brain ROI, tg-ArcSwe and tgSwe showed elevated SUVR compared with wt mice in hippocampus (Fig. 4b ) and the cortex (Fig. 4c) Soluble Aβ aggregates and total Aβ40 and Aβ42 levels in brain and cerebellum were analysed with ELISA in homogenates obtained from mice that underwent PET. With age, there was an increase in Aβ in transgenic mouse brain (Fig. 6a-c) . While soluble Aβ aggregates were highest in 18 m tg-ArcSwe (Fig. 6a) , tg-ArcSwe did not have significantly more Aβ40 (Fig. 6b , p < 0.999) and Aβ42 (Fig. 6c , p < 0.077) than tg-Swe brain. In cerebellum of tg-ArcSwe, there was an increase with age in soluble Aβ aggregates (Fig. 6d) , total Aβ40 (Fig. 6e) , and total Aβ42 (Fig. 6f) , while tg-Swe had effectively no Aβ in cerebellum. The levels of soluble Aβ aggregates ( Fig. 7a and b ) and total Aβ40 (Fig. 7c) were compared to SUVs obtained based on ex vivo measured radioactivity and from PET image analysis by Pearson's correlation. The ex vivo derived SUV brain correlated well with levels of soluble Aβ aggregates (Fig. 7a, p n ¼ 3, tg-Swe: n ¼ 2, wt: n ¼ 3). X.T. Fang et al. NeuroImage 184 (2019) 881-888 In vitro binding properties of di-scFv 3D6-8D3 (Fig. S1a) were investigated with ELISA. The 58 kDa size (Fig. S1b) di-scFv 3D6-8D3 displayed similar TfR binding as scFv 8D3, indicating that fusion to scFv 3D6 did not affect TfR binding (Fig. S1c) . The binding of di-scFv 3D6-8D3 to different conformations of Aβ was also investigated by comparing binding to both monomeric and protofibrillar Aβ (Fig. S1d) . Neither di-scFv 3D6-8D3 nor the full-size variant, 3D6, had preferential binding dependent on Aβ conformation, unlike RmAb158-scFv8D3 which showed conformation-specific preference for protofibrillar Aβ (Fig. S1d, right) , similar to previous reports (Englund et al., 2007; Hultqvist et al., 2017) . Further, di-scFv 3D6-8D3 displayed brain 30-fold higher concentrations than observed for unmodified IgG at 2 h post administration (Fig. S1e) , indicating highly efficient TfR mediated transcytosis across the BBB.
In order to investigate biodistribution, organs were isolated and retained radioactivity was measured post-perfusion (Fig. S2) . Initially, there was a large amount of radioactivity present in kidney, spleen, and urine (8 and 14 h). After 24 h, little radioactivity was left in any organ (<0.1%), indicating there was no peripheral retention. The initial high concentration in kidney and in urine suggested renal clearance of di-scFv 3D6-8D3.
Discussion
The aim was to develop a recombinantly designed fusion protein that functions as a PET radioligand for visualization of Aβ in brain. By constructing a fusion protein based on recombinant expression of two scFvs with no Fc domain, half-life in blood was considerably reduced compared with larger antibody-based PET ligands described previously Sehlin et al., 2016; Syv€ anen et al., 2017) . Moreover, removing the Fc domain likely minimizes immune system interaction and thereby potential immune related side-effects.
Bispecific di-scFv [ 124 I]3D6-8D3 was transported across the BBB rapidly, and was able to bind intra-brain Aβ. Brain concentrations of [ 124 I]3D6-8D3 were highest in old tg-ArcSwe, i.e. the group that also displayed highest levels of soluble Aβ aggregates quantified with ELISA. As standard in brain Aβ PET imaging, quantification of specific binding was done using cerebellum as reference region for generation of SUVR in regions known to be affected by Aβ aggregation. The rationale for using cerebellum as reference is that it is generally assumed that it is void of disease related Aβ pathology. However, as shown here (Fig. 6d-f ) there appeared to be some Aβ pathology detectable in cerebellum of old tgArcSwe, but not tg-Swe . This explains why SUVR were elevated in tg-Swe compared with tg-ArcSwe (Fig. 4) , although absolute levels of di-scFv [ 124 I]3D6-8D3 were higher in tg-ArcSwe.
Hence, the default assumption that cerebellum is a suitable reference region for Aβ detecting radioligands should be considered with caution, and validation should be performed. Despite potential underestimation of specific binding, due to above discussed pathology appearance in cerebellum, di-scFv [ 124 I]3D6-8D3 was shown to be sensitive to dynamic changes in Aβ pathology with age, both with SUVR and total SUV. Observed signal correlated most to brain concentrations of soluble Aβ aggregates (Fig. 7) , even though di-scFv 3D6-8D3 binds to a general epitope present on most forms of Aβ (Fig. 1) C]PIB. This increase in sensitivity may result from di-scFv 3D6-8D3 not only binding to the same target as PIB, but also to a whole other variety of Aβ species leading to a larger pool of potential binding and thus could explain the larger dynamic range. As such, antibody-based radioligands may potentially visualize more subtle changes in Aβ levels than conventional PET radioligands based on small molecules, e.g. after therapeutic treatment decreasing Aβ production, or increasing Aβ clearance.
The di-scFv format shows remarkable pharmacokinetic improvements over our previous larger fusion proteins, indicating that size reduction leads to shorter half-life in blood, likely due to renal clearance of di-scFv 3D6-8D3 Sehlin et al., 2016; Syv€ anen et al., 2017) .
While here we used 3D6, which binds specifically to the first five amino acids of Aβ, it is possible to use other Aβ antibodies binding to other epitopes, or in a longer perspective antibodies directed against other pathogenic proteins (e.g. α-synuclein, tau, TDP43). It is also likely that use of smaller binders (single domain antibodies, affibodies) will result in even faster blood clearance. One major advantage of antibodies is that they specifically bind to certain epitopes or conformations, allowing for creation of highly specific PET radioligands.
We believe that this study demonstrates the general usage of antibody-based small fusion proteins engineered for BBB passage, as they can be used for imaging other brain targets related to a myriad of diseases. As such, antibody-based PET may today serve as a general noninvasive method of disease visualization and tracking in mouse models of pathology and may in the future, when novel 18 F-labelling methods have been developed, also be applied as clinical radioligands.
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